VPC
PTCT icon

Vestal Point Capital’s PTC Therapeutics PTCT Stock Holding History

Vestal Point Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-80,000
Closed -$2.97M – 88
2024
Q3 		$2.97M Sell
80,000
-10,000
-11% -$335K 0.23% 57
2024
Q2 		$2.75M Buy
+90,000
New +$2.92M 0.21% 52

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vestal Point Capital's PTCT Position: Q4 2024 in Review

Vestal Point Capital sold out of PTC Therapeutics (PTCT) in Q4 2024, closing a stake of 80,000 shares — an estimated $2.97M sold.

Vestal Point Capital first reported a position in PTCT in Q2 2024 and held it in 2 quarters. The position peaked at $2.97M in Q3 2024. 239 funds tracked by Wall St. Rank hold PTCT as of Q4 2024.

  • Vestal Point Capital reported no remaining PTC Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Vestal Point Capital sold 80,000 PTC Therapeutics shares in Q4 2024, an estimated $2.97M.
  • Vestal Point Capital first reported a position in PTC Therapeutics in Q2 2024 and held it in 2 quarters.
  • Vestal Point Capital's PTC Therapeutics position peaked at $2.97M in Q3 2024.
  • 239 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2024.

Based on Vestal Point Capital's 13F filing for Q4 2024, filed 14 Feb 2025.